Dysplasia in ulcerative colitis--clinical consequences?

Area of Science:

• Gastroenterology
• Oncology
• Pathology

Background:

• Patients with longstanding extensive or total ulcerative colitis (UC) have a 6- to 10-times higher risk of colorectal cancer (CRC) compared to the general population.
• Surveillance programs aim to detect dysplasia through complete colonoscopies with biopsies to identify individuals prone to CRC for prophylactic colectomy.

Purpose of the Study:

• To review current recommendations and practical issues in colonoscopic surveillance for high-risk ulcerative colitis patients.
• To discuss the role of dysplasia detection and its limitations in predicting colorectal cancer development.

Main Methods:

• Review of recommendations from the Swedish Gastroenterological Association regarding surveillance in UC patients.
• Discussion of inter- and intra-observer variability in dysplasia assessment and the influence of active inflammation.

Main Results:

• Screening colonoscopies are recommended 8-10 years after disease onset, with surveillance intervals not exceeding 2 years.
• High-grade dysplasia, certain dysplasia-associated lesions or masses, or confirmed multifocal low-grade dysplasia are indications for proctocolectomy.
• Management of unifocal low-grade dysplasia remains controversial, with options including proctocolectomy or intensified surveillance.

Conclusions:

• Regular colonoscopic surveillance is the safest approach for UC patients at high risk of CRC.
• Dysplasia is a valuable prognostic marker but has limitations; enhanced surveillance markers may offer improved management.
• A combination of enhanced colonoscopic surveillance and sensitive markers is suggested for optimal management of increased CRC risk in UC patients.